Study Objective: Compare longitudinal HIV-1 antibody responses among HIV-1 infected participants that either did or did not...
REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....
A5225/HiFLAC is a Phase I/II dose escalation and validation study of the safety, tolerability, and therapeutic effect of an...
PK, safety and acceptability data and practical guidance on the optimal dosing of new more child-friendly formulations of...
ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...
